MedPath

Effects of alkalization therapy on chemotherapy in metastatic or recurrent pancreatic cancer, retrospective study

Not Applicable
Conditions
Pancreatic cancer
Registration Number
JPRN-UMIN000035659
Lead Sponsor
Japanese Society on Inflammation and Metabolism in Cancer
Brief Summary

The mean urine pH was significantly higher after the alkalization therapy (6.85 +- 0.74 vs. 6.39 +- 0.92; p < 0.05). The median overall survival from the start of alkalization therapy of the patients with high urine pH (< 7.0) was significantly longer than those with low urine pH (<= 7.0)(16.1 vs. 4.7 months; p < 0.05).

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
28
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who could not follow the alkalization therapy and/or visited our clinic less than 3 times.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath